Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | JAK1 | P23458 | 1/20 | 0.55 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.55 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.55 |
| ▸ | STS | P08842 | 1/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | YAP1 | P46937 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20503925 | 1.00 | JAK2 (0.55) | JAK2JAK1PRMT5WDR77STS | |
| SCHEMBL942191 | 1.00 | JAK2 (0.55) | JAK2JAK1PRMT5WDR77STS | |
| SCHEMBL3152405 | 0.93 | USP30 (0.56) | JAK2JAK1PRMT5WDR77USP30 | |
| SCHEMBL3152395 | 0.93 | USP30 (0.56) | JAK2JAK1PRMT5WDR77USP30 | |
| SCHEMBL12607067 | 0.93 | PRMT5 (0.56) | JAK2JAK1PRMT5WDR77STS | |
| SCHEMBL12607070 | 0.93 | PRMT5 (0.56) | JAK2JAK1PRMT5WDR77STS | |
| SCHEMBL29117319 | 0.93 | PRMT5 (0.56) | JAK2JAK1PRMT5WDR77STS | |
| SCHEMBL3249107 | 0.92 | STS (0.58) | JAK2JAK1PRMT5WDR77STS | |
| SCHEMBL9938446 | 0.90 | PRMT5 (0.51) | JAK2JAK1PRMT5WDR77STS | |
| SCHEMBL16903418 | 0.90 | JAK2 (0.53) | JAK2JAK1PRMT5WDR77STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190831-A1 | TRANSTHYRETIN STABILIZING COMPOUNDS | PROTEGO BIOPHARMA, INC. | 2024-06-13 | — | — | US | disclosed |
| WO-2024059806-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-03-21 | — | — | WO | disclosed |
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-07-25 | — | — | US | disclosed |
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-07-25 | — | — | US | disclosed |
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-07-25 | — | — | US | disclosed |
| WO-2023009585-A2 | TRANSTHYRETIN STABILIZING COMPOUNDS | PROTEGO BIOPHARMA, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023009585-A2 | TRANSTHYRETIN STABILIZING COMPOUNDS | PROTEGO BIOPHARMA, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20210221809-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery ENSCM (FR) | 2021-07-22 | — | — | US | disclosed |
| US-20210221809-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery ENSCM (FR) | 2021-07-22 | — | — | US | disclosed |
| US-10995089-B2 | Zaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2021-05-04 | — | — | US | disclosed |
| EP-1950198-A1 | PROCESS FOR PRODUCTION OF BENZYLOXYPYRROLIDINE DERIVATIVE, AND PROCESS FOR PRODUCTION OF HYDROCHLORIDE SALT POWDER OF OPTICALLY ACTIVE BENZYLOXYPYRROLIDINE DERIVATIVE | Toray Fine Chemicals Co., Ltd. (JP) | 2008-07-30 | — | — | EP | disclosed |
| EP-1947083-A1 | PROCESS FOR PRODUCTION OF ARALKYLOXYPYRROLIDINE DERIVATIVE | Kaneka Corporation (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-20080021005-A1 | Pegylated Ion Channel Modulating Compounds | CARDIOME PHARMA CORP. (CA) | 2008-01-24 | — | — | US | disclosed |
| WO-2007119463-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES AS TPK1 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007119463-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES AS TPK1 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-25 | — | — | WO | disclosed |
| US-7148242-B2 | N-formyl hydroxylamine compounds, compositions and methods of use | NOVARTIS AG (CH) | 2006-12-12 | — | — | US | disclosed |
| EP-1401828-B1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | VICURON PHARM INC (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1401828-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | Vicuron Pharmaceuticals, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | VICURON HOLDINGS LLC | 2003-03-06 | — | — | US | disclosed |
| WO-2002102790-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | VICURON PHARMACEUTICALS INC. (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021005-A1 | Pegylated Ion Channel Modulating Compounds | KCNN3, KCNN2, KCNN1 | JAK2 3132/4885JAK1 4609/4885PRMT5 4217/4885 |
| US-10995089-B2 | Zaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK3 | JAK2 203/4885JAK1 290/4885PRMT5 2083/4885 |
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | PDF, HNMT, AADAC | JAK2 3671/4885JAK1 3089/4885PRMT5 523/4885 |
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK3 | JAK2 323/4885JAK1 479/4885PRMT5 735/4885 |
| US-20210221809-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK3 | JAK2 323/4885JAK1 479/4885PRMT5 735/4885 |
| US-20240190831-A1 | TRANSTHYRETIN STABILIZING COMPOUNDS | TTR, TTPA, MTPN | JAK2 4781/4885JAK1 4773/4885PRMT5 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.